Fingerprint
Dive into the research topics of 'TBCRC023: A randomized phase II neoadjuvant trial of lapatinib plus trastuzumab without chemotherapy for 12 versus 24 weeks in patients with HER2-positive breast cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically